Clik here to view.
武田公布2019财年第二季度稳健业绩并上调全年利润指引
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502, NYSE:TAK)： 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20191104006113/zh-CN/ 与2018财年上半年形式营收2...
View ArticleClik here to view.
オクタファルマ、心臓手術を受ける患者での後天的フィブリノゲン欠損症の治療薬としてのfibryga®に関するデータの公表を発表
スイス・ラーヘン （ビジネスワイヤ） — オクタファルマは、フィブリノゲン濃縮製剤fibryga®が、心臓手術中に重度の出血を呈する患者でクリオプレシピテートの有効な代替となることを示す新しいデータが公表されたと発表しました。データは最近、米国医師会誌（JAMA）に掲載されました1。...
View ArticleClik here to view.
Takeda and MD Anderson Announce Collaboration to Accelerate the Development...
HOUSTON & OSAKA, Japan The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement...
View ArticleClik here to view.
CANbridge Receives Hong Kong Department of Health Market Approval for NERLYNX®
BEIJING CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that it...
View ArticleClik here to view.
Seattle Genetics and BeiGene Announce Global License Agreement for Advanced...
BOTHELL, Wash. & BEIJING & CAMBRIDGE, Mass. Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have entered into a license...
View ArticleClik here to view.
Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing...
SAN DIEGO Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 –...
View ArticleClik here to view.
メアリー・ケイ財団、がん研究と家庭内暴力シェルター助成金として310万ドルを授与
ダラス （ビジネスワイヤ） — メアリー・ケイ財団は先ごろ、米国内のがん研究と家庭内暴力シェルター助成金へ300万ドル以上を授与しました。メアリー・ケイ財団は、女性に影響を与えるがんの撲滅を全体的な目的として1996年に設立されました。2000年に財団は活動を広げ、その使命の一つに家庭内暴力の終焉を含めました。...
View ArticleClik here to view.
Samsung Bioepis Enters into Commercialization Agreement for Next-Generation...
INCHEON, Korea Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by...
View ArticleClik here to view.
Promega Enters Global Collaboration with Merck to Develop Microsatellite...
MADISON, Wis. Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite...
View ArticleClik here to view.
Takeda to Highlight Expanded Portfolio of Products Across Oncology and...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American...
View ArticleClik here to view.
路胜生物与迈杰（苏州）在中国合作开发领先的癌症检测
苏州 新加坡领先的基因组医学公司路胜生物苏州有限公司（简称路胜）宣布将与迈杰转化医学研究（苏州）有限公司 【简称（迈杰（苏州）】建立战略合作伙伴关系，共同开发癌症检测，包括伴随诊断，这一举动不仅造福广大癌症患者，而且为新药研发公司提供更多的创新合作机会。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
MEDx (Suzhou) and Lucence Partner to Co-Develop Cutting-Edge Cancer-Care Tests
SUZHOU, China MEDx (Suzhou) Translational Medicine, and Singapore-based Lucence – a leading genomic medicine company – today announced an agreement to pursue a strategic partnership in China to...
View ArticleClik here to view.
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs)...
JERUSALEM & PARSIPPANY, N.J. & INCHEON, South Korea Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Celltrion, Inc., (KRX...
View ArticleClik here to view.
プロメガがキイトルーダと共用するためのマイクロサテライト不安定性（MSI）コンパニオン診断薬の開発でメルクと世界規模の協業に入る
米ウィスコンシン州マディソン （ビジネスワイヤ） —...
View ArticleClik here to view.
Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of...
View ArticleClik here to view.
South Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance...
TORONTO & SEOUL, South Korea Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to...
View ArticleClik here to view.
武田和MD安德森宣布合作以加快开发临床阶段、开箱即用型CAR NK细胞治疗平台
休斯敦和日本大阪 (美国商业资讯)–德克萨斯大学MD安德森癌症中心(The University of Texas MD Anderson Cancer Center)和武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3...
ALAMEDA, Calif. Exelixis, Inc. (Nasdaq: EXEL) announced today that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive results from a phase 3 pivotal trial of...
View ArticleClik here to view.
Gynesonics Names Kelly U. Petrucci Vice President of Healthcare Economics and...
REDWOOD CITY, Calif. Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device...
View ArticleClik here to view.
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo)...
View Article